Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications

Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors

(2017) Beatrice S Melin et al.   NATURE GENETICS

Correlation of immune phenotype with IDH mutation in diffuse glioma

(2017) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Combining Epigenetic and Immunotherapy to Combat Cancer

(2016) Katherine B. Chiappinelli et al.   CANCER RESEARCH

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

(2016) Michele Ceccarelli et al.   CELL

Editing DNA Methylation in the Mammalian Genome

(2016) X. Shawn Liu et al.   CELL

Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future

(2016) Ricky Chen et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Advances in immunotherapy for the treatment of glioblastoma

(2016) Amanda Tivnan et al.   JOURNAL OF NEURO-ONCOLOGY

Advances in the molecular genetics of gliomas — implications for classification and therapy

(2016) Guido Reifenberger et al.   Nature Reviews Clinical Oncology

Targeting the cancer epigenome for therapy

(2016) Peter A. Jones et al.   NATURE REVIEWS GENETICS

Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway

(2016) Jun Feng et al.   Biomed Research International

Relation between Established Glioma Risk Variants and DNA Methylation in the Tumor

(2016) Anna M. Dahlin et al.   PLoS One

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion

(2015) Kensuke Tateishi et al.   CANCER CELL

DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors

(2015) Tali Mazor et al.   CANCER CELL

DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension

(2015) Jonathan D. Licht   CELL

Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy

(2015) M. Maio et al.   CLINICAL CANCER RESEARCH

Epigenetic modifications of the immune system in health and disease

(2015) Yuuki Obata et al.   IMMUNOLOGY AND CELL BIOLOGY

New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma

(2015) Lilia Dimitrov et al.   International Journal of Medical Sciences

Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients

(2015) Pilar Mur et al.   JOURNAL OF NEURO-ONCOLOGY

Insulator dysfunction and oncogene activation in IDH mutant gliomas

(2015) William A. Flavahan et al.   NATURE

Integrated genomic characterization of IDH1-mutant glioma malignant progression

(2015) Hanwen Bai et al.   NATURE GENETICS

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

(2015) Jeanette E. Eckel-Passow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Genome-wide CpG island methylation and intergenic demethylation propensities vary among different tumor sites

(2015) Seung-Tae Lee et al.   NUCLEIC ACIDS RESEARCH

Pan-cancer stratification of solid human epithelial tumors and cancer cell lines reveals commonalities and tissue-specific features of the CpG island methylator phenotype

(2015) Francisco Sánchez-Vega et al.   Epigenetics & Chromatin

Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy

(2015) Jeenah Park et al.   Epigenomics

Epigenetic treatment of solid tumours: a review of clinical trials

(2015) Clara Nervi et al.   Clinical Epigenetics

Pharmacological DNA demethylation: Implications for cancer immunotherapy

(2015) David Roulois et al.   OncoImmunology

Alterations of immune response of non-small cell lung cancer with Azacytidine

(2015) John Wrangle et al.   Oncotarget

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

(2015) Sevin Turcan et al.   Oncotarget

Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma

(2014) Benedikt Wiestler et al.   ACTA NEUROPATHOLOGICA

Biological significance of the CpG island methylator phenotype

(2014) Hiromu Suzuki et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells

(2014) Mario L. Suvà et al.   CELL

Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin

(2014) Katherine A. Hoadley et al.   CELL

Characterizing DNA methylation alterations from The Cancer Genome Atlas

(2014) Daniel J. Weisenberger   JOURNAL OF CLINICAL INVESTIGATION

Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH

(2014) J. Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

A vaccine targeting mutant IDH1 induces antitumour immunity

(2014) Theresa Schumacher et al.   NATURE

Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial

(2014) B. Wiestler et al.   NEURO-ONCOLOGY

Pan-cancer patterns of DNA methylation

(2014) Tania Witte et al.   Genome Medicine

Sox2 Promotes Malignancy in Glioblastoma by Regulating Plasticity and Astrocytic Differentiation

(2014) Artem D. Berezovsky et al.   NEOPLASIA

Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors

(2013) Pilar Mur et al.   ACTA NEUROPATHOLOGICA

Interplay between the Cancer Genome and Epigenome

(2013) Hui Shen et al.   CELL

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

The Sox Family of Transcription Factors: Versatile Regulators of Stem and Progenitor Cell Fate

(2013) Abby Sarkar et al.   Cell Stem Cell

IDH1 and IDH2 Mutations in Gliomas

(2013) Adam L. Cohen et al.   Current Neurology and Neuroscience Reports

The future of epigenetic therapy in solid tumours—lessons from the past

(2013) Nilofer Azad et al.   Nature Reviews Clinical Oncology

IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival

(2013) S. Leu et al.   NEURO-ONCOLOGY

Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective

(2013) B. Wiestler et al.   NEURO-ONCOLOGY

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

(2013) W. Wick et al.   NEUROLOGY

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

(2012) Pierre Bady et al.   ACTA NEUROPATHOLOGICA

Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma

(2012) Dominik Sturm et al.   CANCER CELL

A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation

(2012) C. G. Duncan et al.   GENOME RESEARCH

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

(2011) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome

(2011) Juan Sandoval et al.   Epigenetics

Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation

(2011) H. Wu et al.   GENES & DEVELOPMENT

Low-grade gliomas in adults

(2011) Nader Sanai et al.   JOURNAL OF NEUROSURGERY

Increased methylation variation in epigenetic domains across cancer types

(2011) Kasper Daniel Hansen et al.   NATURE GENETICS

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

(2011) A. L. Rivera et al.   NEURO-ONCOLOGY

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry

(2010) María Berdasco et al.   DEVELOPMENTAL CELL

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2

(2010) M. Labussiere et al.   NEUROLOGY

DNA methylation and cellular reprogramming

(2010) Daniel D. De Carvalho et al.   TRENDS IN CELL BIOLOGY

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Epigenetics in cancer

(2009) S. Sharma et al.   CARCINOGENESIS

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE